[go: up one dir, main page]

NO932866D0 - Dimer av molekylaervariant av apolipoprotein og fremgangsmaater for fremstilling derav - Google Patents

Dimer av molekylaervariant av apolipoprotein og fremgangsmaater for fremstilling derav

Info

Publication number
NO932866D0
NO932866D0 NO932866A NO932866A NO932866D0 NO 932866 D0 NO932866 D0 NO 932866D0 NO 932866 A NO932866 A NO 932866A NO 932866 A NO932866 A NO 932866A NO 932866 D0 NO932866 D0 NO 932866D0
Authority
NO
Norway
Prior art keywords
apolipoprotein
dimer
pct
apo
dimers
Prior art date
Application number
NO932866A
Other languages
English (en)
Other versions
NO315076B1 (no
NO932866L (no
Inventor
Cesare Cirtori
Guido Franceschini
Lars Abrahmsen
Erik Holmgren
Mats Lake
Bjoern Nilsson
Joanna Chmielewska
Peter Lind
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO932866L publication Critical patent/NO932866L/no
Publication of NO932866D0 publication Critical patent/NO932866D0/no
Publication of NO315076B1 publication Critical patent/NO315076B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19932866A 1991-12-13 1993-08-12 Dimerpreparat av molekyl¶rvariant av apolipoprotein og fremgangsmåter for fremstilling og anvendelse derav, til fremstilling av et medikamentfor behandling av aterosklerose og kardiovaskul¶re sykdommer NO315076B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103701A SE9103701D0 (sv) 1991-12-13 1991-12-13 Apolipoprotein
PCT/SE1992/000858 WO1993012143A1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof

Publications (3)

Publication Number Publication Date
NO932866L NO932866L (no) 1993-08-12
NO932866D0 true NO932866D0 (no) 1993-08-12
NO315076B1 NO315076B1 (no) 2003-07-07

Family

ID=20384608

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19932866A NO315076B1 (no) 1991-12-13 1993-08-12 Dimerpreparat av molekyl¶rvariant av apolipoprotein og fremgangsmåter for fremstilling og anvendelse derav, til fremstilling av et medikamentfor behandling av aterosklerose og kardiovaskul¶re sykdommer

Country Status (28)

Country Link
US (2) US5876968A (no)
EP (1) EP0571602B1 (no)
JP (1) JPH07502892A (no)
AT (1) ATE242269T1 (no)
AU (2) AU3175593A (no)
BG (1) BG61451B1 (no)
BR (1) BR9205640A (no)
CA (1) CA2103996C (no)
CZ (1) CZ289879B6 (no)
DE (1) DE69233092T2 (no)
DK (1) DK0571602T3 (no)
EE (1) EE03058B1 (no)
ES (1) ES2199939T3 (no)
FI (1) FI115771B (no)
HU (2) HU217203B (no)
IL (1) IL103956A (no)
MX (1) MX9207224A (no)
NO (1) NO315076B1 (no)
NZ (2) NZ280516A (no)
PL (3) PL172544B1 (no)
PT (1) PT571602E (no)
RO (1) RO115636B1 (no)
RU (1) RU2134696C1 (no)
SE (1) SE9103701D0 (no)
SG (1) SG47453A1 (no)
SK (1) SK86893A3 (no)
WO (1) WO1993012143A1 (no)
ZA (1) ZA928989B (no)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
US6743778B2 (en) 2000-04-21 2004-06-01 Amgen Inc. Apo-AI/AII peptide derivatives
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
AU2002362612B2 (en) * 2001-09-28 2007-11-15 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
JP2006502976A (ja) * 2002-05-17 2006-01-26 エスペリオン セラピューティクス，インコーポレイテッド 虚血再潅流を治療する方法および組成物
WO2003096983A2 (en) 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2005051413A2 (en) * 2003-11-26 2005-06-09 Novartis Ag Disease associated genes
CA2549529A1 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US9487575B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
KR20080007491A (ko) 2005-04-29 2008-01-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
KR100719389B1 (ko) 2005-10-18 2007-05-17 주식회사 녹십자 인간혈장으로부터 아포리포단백질 ａ-ｉ을 분리 정제하는방법
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
WO2008017906A1 (en) * 2006-08-10 2008-02-14 Plantechno S.R.L. In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
EP2682400B1 (en) 2007-08-28 2017-09-20 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009050266A2 (en) * 2007-10-19 2009-04-23 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
MX2010004514A (es) 2007-10-23 2010-07-28 Cleveland Clinic Foundation Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
MX351819B (es) 2008-11-10 2017-10-30 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
CA2751342C (en) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
PT3431076T (pt) 2009-06-10 2021-10-26 Arbutus Biopharma Corp Formulação lipídica melhorada
EP2810643A3 (en) 2009-08-14 2015-03-11 Alnylam Pharmaceuticals Inc. Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8921304B2 (en) * 2009-12-14 2014-12-30 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) * 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
JP5893611B2 (ja) 2010-06-03 2016-03-23 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性剤の送達のための生分解性脂質
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
DK2663548T3 (en) 2011-01-11 2017-07-24 Alnylam Pharmaceuticals Inc PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
WO2012109162A1 (en) 2011-02-07 2012-08-16 Cerenis Therapeutics Holding S.A. Lipoprotein complexes and manufacturing and uses thereof
AU2012268970B2 (en) 2011-06-15 2016-01-28 Navigo Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
EP2748191A1 (en) 2011-08-25 2014-07-02 F.Hoffmann-La Roche Ag Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CN106488987A (zh) 2014-05-02 2017-03-08 塞勒尼斯医疗控股公司 Hdl疗法标志物
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
AU2016293063B2 (en) 2015-07-16 2018-11-08 Navigo Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
JP2019526526A (ja) 2016-05-04 2019-09-19 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ペプチドリンカーを含む化学的部分の部位特異的カップリングのための標的化合物
WO2018029158A1 (en) 2016-08-11 2018-02-15 Repligen Corporation Alkaline stable fc—binding proteins for affinity chromatography
TW201919686A (zh) 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 脫輔基子(apomers)
ES2984285T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargómeros
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
IL284097B2 (en) 2018-12-18 2025-10-01 Navigo Proteins Gmbh FOLR1-binding proteins for cancer diagnosis and treatment
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
IL317446A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating acute conditions using complexes based on lipid-binding proteins
CA3258787A1 (en) 2022-06-10 2023-12-14 Stanislas FAGUER METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
AU2024207875A1 (en) 2023-01-13 2025-07-24 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
PL172168B1 (pl) 1997-08-29
HU9302344D0 (en) 1994-01-28
NO315076B1 (no) 2003-07-07
WO1993012143A1 (en) 1993-06-24
CZ289879B6 (cs) 2002-04-17
PL300262A1 (en) 1994-03-07
DE69233092T2 (de) 2004-07-08
EP0571602B1 (en) 2003-06-04
PL172544B1 (pl) 1997-10-31
FI115771B (fi) 2005-07-15
JPH07502892A (ja) 1995-03-30
NZ280516A (en) 1997-06-24
IL103956A0 (en) 1993-05-13
PL171907B1 (pl) 1997-06-30
MX9207224A (es) 1993-06-01
FI933557L (fi) 1993-08-12
SE9103701D0 (sv) 1991-12-13
DK0571602T3 (da) 2003-10-06
SG47453A1 (en) 1998-04-17
RO115636B1 (ro) 2000-04-28
ES2199939T3 (es) 2004-03-01
FI933557A0 (fi) 1993-08-12
HU211667A9 (en) 1995-12-28
CA2103996C (en) 2007-01-16
HUT70270A (en) 1995-09-28
US5876968A (en) 1999-03-02
BG98036A (bg) 1994-05-27
HU217203B (hu) 1999-12-28
AU703283B2 (en) 1999-03-25
DE69233092D1 (de) 2003-07-10
PT571602E (pt) 2003-10-31
SK86893A3 (en) 1994-04-06
AU5947396A (en) 1996-10-31
NO932866L (no) 1993-08-12
US6617134B1 (en) 2003-09-09
IL103956A (en) 1998-09-24
RU2134696C1 (ru) 1999-08-20
CA2103996A1 (en) 1993-06-14
NZ246223A (en) 1996-06-25
AU3175593A (en) 1993-07-19
BR9205640A (pt) 1994-05-03
EE03058B1 (et) 1997-12-15
BG61451B1 (en) 1997-08-29
CZ158993A3 (en) 1994-07-13
ZA928989B (en) 1993-05-17
ATE242269T1 (de) 2003-06-15
EP0571602A1 (en) 1993-12-01

Similar Documents

Publication Publication Date Title
NO932866D0 (no) Dimer av molekylaervariant av apolipoprotein og fremgangsmaater for fremstilling derav
RU93054168A (ru) Димер молекулярного варианта аро-липопротеина, способ его получения, фармацевтическая композиция на его основе
FI962591A0 (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
IL113941A (en) Perfluoroalkyl ketone inhibitors of elastase processes for making the same and pharmaceutical compositions containing them
DE3662041D1 (en) New carboxylic acid derivatives, their manufacturing process, use and medicines containing these compounds
RU95100773A (ru) Новые сложные эфиры серной кислоты сахарных спиртов
ATE157007T1 (de) 6-cyclohexyl-2'-0-methyl-adenosine hydrat und verwendungengen davon
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
FI92320C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
ATE232387T1 (de) Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
RU94000064A (ru) Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции
CA2208682A1 (en) Fibrinogen receptor antagonists having substituted .beta.-amino acid residues and pharmaceutical compositions comprising the same
ES2082390T3 (es) Acido gamma-linolenico para la preparacion de un medicamento para impedir la reoclusion de las arterias.
GR3025064T3 (en) New hydrazino and hydroxyamino-14beta-hydroxyandrostane derivatives active on the cardio-vascular system, processes for their preparation and pharmaceutical compositions containing same
CA2280960A1 (en) Oxirancarboxylic acids for the treatment of diabetes
SE9301324D0 (sv) New method of treatment
ITMI920082A1 (it) Derivati solforati di acidi biliari
DE69420574D1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
MX9203171A (es) Composiciones farmaceuticas para el tratamiento de la hipertension arterial.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees